Moleculin authorizes reverse split: what it means for Moleculin Biotech stock

Published on 10/16/2026 at 00:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moleculin Biotech stock faces a 3,861,894-share plan increase. The board can choose a 1-for-20 ratio before October 9, 2027.

Capital structure and trial timeline

Shareholders approved reverse split authority ranging from 1-for-2 to 1-for-20 on October 9, 2026.
Moleculin completed Part A enrollment in its MIRACLE trial on September 29, 2026, with a first-quarter 2027 readout planned.
Moleculin's next earnings date is November 9, 2026.

MBRX, US60855D4088, Illustration mit AI erstellt.

Moleculin Biotech (ISIN US60855D4088) received authority on October 9, 2026, to execute a reverse stock split at a ratio from 1-for-2 to 1-for-20. The vote also approved an increase of 3,861,894 shares in the company's 2024 Stock Plan, according to StockTitan.

What changed on October 9

The amended plan now authorizes 3,875,999 shares, while 19,477,380 common shares were outstanding and entitled to vote as of August 19, 2026. The reverse split authority remains at the board's discretion and can be used before the one-year anniversary of the annual meeting.

The proposal received 5,738,901 votes in favor and 2,488,513 against. The annual meeting also elected five directors and ratified Grant Thornton as the independent registered public accounting firm for the year ending December 31, 2026.

Clinical progress supplies the counterpoint

Moleculin said on October 7, 2026, that Part A enrollment in the MIRACLE Phase 2/3 trial had been completed on September 29, 2026. The company expects a comprehensive Part A data readout in the first quarter of 2027.

A separate company release described a pooled cardiac-safety analysis of 90 patients across five clinical trials on September 28, 2026. The result supports continued evaluation of Annamycin, but the company also stated that significant additional financing will be required for its clinical trials.

What does the approval mean?

The capital measures give Moleculin flexibility over its share structure while expanding the plan by 3,861,894 shares. That combination puts financing capacity and potential dilution alongside the clinical milestones as central issues for the biotechnology company.

The next reporting dates

The next earnings report is listed for November 9, 2026, by Investing.com. Moleculin's planned first-quarter 2027 MIRACLE data readout is the next stated clinical milestone.

Financing remains central

Moleculin is a Phase 3 clinical-stage pharmaceutical company developing Annamycin for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. Its financing needs and the 2027 trial readout now frame the significance of the October 9 shareholder vote.